Accumetrics’ VerifyNow P2Y12 Test is now CE marked for prognostic use in identifying patients with high residual platelet reactivity on antiplatelet therapy and at greater risk for future cardiovascular events.
Accumetrics said its VerifyNow System helps physicians determine an individual’s platelet response to multiple antiplatelet agents.
Addressing every major antiplatelet drug including aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient) and clopidogrel (Plavix)) and GP IIb/IIIa inhibitors (e.g. ReoPro and Integrilin), the VerifyNow System provides valuable information to help physicians make informed treatment decisions.
Accumetrics president and CEO Timothy Still said also considering the recent inclusion of platelet reactivity testing in both the ACCF/AHA UA/NSTEMI Guidelines and the STS/SCA Blood Conservation Guidelines, the VerifyNow System is making a significant impact on how physicians are treating their cardiovascular patients.
The VerifyNow P2Y12 Test is not currently indicated for use in risk assessment in the US.
CE marking of this use is recognized in the European Economic Area.